|
1
|
Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW,
Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava
P, et al: Phase II study of gemcitabine and oxaliplatin in
combination with bevacizumab in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:1898–1903. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aravalli RN, Cressman EN and Steer CJ:
Cellular and molecular mechanisms of hepatocellular carcinoma: An
update. Arch Toxicol. 87:227–247. 2013. View Article : Google Scholar
|
|
3
|
Ma WL, Jeng LB, Lai HC, Liao PY and Chang
C: Androgen receptor enhances cell adhesion and decreases cell
migration via modulating β1-integrin-AKT signaling in
hepatocellular carcinoma cells. Cancer Lett. 351:64–71. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ng L, Tung-Ping Poon R, Yau S, Chow A, Lam
C, Li HS, Chung-Cheung Yau T, Law WL and Pang R: Suppression of
actopaxin impairs hepatocellular carcinoma metastasis through
modulation of cell migration and invasion. Hepatology. 58:667–679.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Villanueva A, Chiang DY, Newell P, et al:
Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology. 135:1972–1983. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhong W, Qin S, Zhu B, Pu M, Liu F, Wang
L, Ye G, Yi Q and Yan D: Oxysterol-binding protein (OSBP)-related
protein 8 (ORP8) increases sensitivity of hepatocellular carcinoma
cells to Fas-mediated apoptosis. J Biol Chem. Jan 16–2015.Epub
ahead of print. View Article : Google Scholar
|
|
7
|
Williams AH, Liu N, van Rooij E and Olson
EN: MicroRNA control of muscle development and disease. Curr Opin
Cell Biol. 21:461–469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Divakaran V and Mann DL: The emerging role
of microRNAs in cardiac remodeling and heart failure. Circ Res.
103:1072–1083. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Rooij E, Sutherland LB, Thatcher JE,
DiMaio JM, Naseem RH, Marshall WS, Hill JA and Olson EN:
Dysregulation of microRNAs after myocardial infarction reveals a
role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA.
105:13027–13032. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Rooij E, Liu N and Olson EN: MicroRNAs
flex their muscles. Trends Genet. 24:159–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Frost RJ and van Rooij E: miRNAs as
therapeutic targets in ischemic heart disease. J Cardiovasc Transl
Res. 3:280–289. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin Z, Murtaza I, Wang K, Jiao J, Gao J
and Li PF: miR-23a functions downstream of NFATc3 to regulate
cardiac hypertrophy. Proc Natl Acad Sci USA. 106:12103–12108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu L, Zhou L, Cheng Y, Sun L, Fan J, Liang
J, Guo M, Liu N and Zhu L: MicroRNA-543 acts as an oncogene by
targeting PAQR3 in hepatocellular carcinoma. Am J Cancer Res.
4:897–906. 2014.PubMed/NCBI
|
|
14
|
Zhang S, Shan C, Kong G, Du Y, Ye L and
Zhang X: MicroRNA-520e suppresses growth of hepatoma cells by
targeting the NF-κB-inducing kinase (NIK). Oncogene. 31:3607–3620.
2012. View Article : Google Scholar
|
|
15
|
He XX, Chang Y, Meng FY, Wang MY, Xie QH,
Tang F, Li PY, Song YH and Lin JS: MicroRNA-375 targets AEG-1 in
hepatocellular carcinoma and suppresses liver cancer cell growth in
vitro and in vivo. Oncogene. 31:3357–3369. 2012. View Article : Google Scholar
|
|
16
|
Li D, Liu Y, Li H, Peng JJ, Tan Y, Zou Q,
Song XF, Du M, Yang ZH, Tan Y, et al: MicroRNA-1 promotes apoptosis
of hepatocarcinoma cells by targeting apoptosis inhibitor-5
(API-5). FEBS Lett. 589:68–76. 2015. View Article : Google Scholar
|
|
17
|
Chen P, Wang BL, Pan BS and Guo W:
MiR-1297 regulates the growth, migration and invasion of colorectal
cancer cells by targeting cyclo-oxygenase-2. Asian Pac J Cancer
Prev. 15:9185–9190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Chi YL, Wang PY, Wang YQ, Zhang
YX, Deng J, Lv CJ and Xie SY: miR-511 and miR-1297 inhibit human
lung adenocarcinoma cell proliferation by targeting oncogene TRIB2.
PLoS One. 7:e460902012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meng X, Franklin DA, Dong J and Zhang Y:
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res.
74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ying TH, Tsai JH, Wu TT, Tsai MT, Su WW,
Hsieh YS and Liu JY: Immunochemical localization of protein kinase
Calpha in the biopsies of human hepatocellular carcinoma. Chin J
Physiol. 51:269–274. 2008.
|
|
23
|
Muche S, Kirschnick M, Schwarz M and
Braeuning A: Synergistic effects of β-catenin inhibitors and
sorafenib in hepatoma cells. Anticancer Res. 34:4677–4683.
2014.PubMed/NCBI
|
|
24
|
Mokkapati S, Niopek K, Huang L, Cunniff
KJ, Ruteshouser EC, deCaestecker M, Finegold MJ and Huff V:
β-catenin activation in a novel liver progenitor cell type is
sufficient to cause hepatocellular carcinoma and hepatoblastoma.
Cancer Res. 74:4515–4525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang J, Park JS, Wei Y, Rajurkar M, Cotton
JL, Fan Q, Lewis BC, Ji H and Mao J: TRIB2 acts downstream of
Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function.
Mol Cell. 51:211–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Morishita A, Zaidi MR, Mitoro A,
Sankarasharma D, Szabolcs M, Okada Y, D'Armiento J and Chada K:
HMGA2 is a driver of tumor metastasis. Cancer Res. 73:4289–4299.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun M, Song CX, Huang H, Frankenberger CA,
Sankarasharma D, Gomes S, Chen P, Chen J, Chada KK, He C, et al:
HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth
and metastasis. Proc Natl Acad Sci USA. 110:9920–9925. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zaidi MR, Okada Y and Chada KK:
Misexpression of full-length HMGA2 induces benign mesenchymal
tumors in mice. Cancer Res. 66:7453–7459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Zhao Z, Xu C, Zhou Z, Zhu Z and You
T: HMGA2 induces transcription factor Slug expression to promote
epithelial-to-mesenchymal transition and contributes to colon
cancer progression. Cancer Lett. 355:130–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luo Y, Li W and Liao H: HMGA2 induces
epithelial-to-mesenchymal transition in human hepatocellular
carcinoma cells. Oncol Lett. 5:1353–1356. 2013.PubMed/NCBI
|
|
31
|
Pentimalli F, Dentice M, Fedele M,
Pierantoni GM, Cito L, Pallante P, Santoro M, Viglietto G, Dal Cin
P and Fusco A: Suppression of HMGA2 protein synthesis could be a
tool for the therapy of well differentiated liposarcomas
overexpressing HMGA2. Cancer Res. 63:7423–7427. 2003.PubMed/NCBI
|
